| Literature DB >> 32606734 |
Jingyu Chen1, Tianyi Liu2, Hui Wang3, Zhipeng Wang1, Yanju Lv4, Yuying Zhao1, Ning Yang1, Xueli Yuan1.
Abstract
PURPOSE: Glioma (GM) usually presents with an aggressive behavior and has a poor survival outcome. The abnormal expression of circular RNAs (circRNAs) has already been detected in GM, and circ_0079586 was found to have an increased expression in GM tumors. PATIENTS AND METHODS: We assessed the differences in the expression of circ_0079586 in GM tissues (N=60) and cell lines (N=5) using qRT-PCR. The clinical value of circ_0079586 was measured by Fisher's exact test and Kaplan-Meier and Cox regression analyses. Circ_0079586 siRNA and vector were transfected into LN229 and U251 cells, respectively, and the transfection was verified by qRT-PCR. Cell growth was evaluated by cell counting kit-8 (CCK-8). Cell apoptosis was measured using flow cytometric assay. Cell metastatic properties were measured by wound scratch and transwell experiments. Subcellular fractionation was used to identify the location of circ_0079586. Dual-luciferase reporter test was utilized to confirm the interaction between miR-183-5p and circ_0079586/MDM4 3'-UTR.Entities:
Keywords: MDM4 protein; circ_0079586; circular RNA; glioma; miR-183-5p
Year: 2020 PMID: 32606734 PMCID: PMC7292368 DOI: 10.2147/OTT.S234758
Source DB: PubMed Journal: Onco Targets Ther ISSN: 1178-6930 Impact factor: 4.147
Figure 1Relative expression of circ_0079586 in GM tissues and cell lines and its clinical significance. (A) Relative expression of circ_0079586 in GM samples and paired non-cancerous samples measured by qRT-PCR. (B) Relative expression of circ_0079586 in GM and normal cell lines measured by qRT-PCR. (C) Kaplan–Meier survival analysis showing correlation between circ_0079586 expression and overall survival in GM patients. **p < 0.01.
Correlation Between circ_0079586 Expression and Clinicopathological Parameters of Glioma Patients
| Clinicopathological Features | No. of Patients | circ_0079586 Expression | ||
|---|---|---|---|---|
| High | Low | |||
| Gender | 0.601 | |||
| Male | 35 | 19 | 16 | |
| Female | 25 | 11 | 14 | |
| Age | 0.143 | |||
| <45 | 44 | 19 | 25 | |
| ≥45 | 16 | 11 | 5 | |
| Family history of cancer | 0.333 | |||
| Yes | 12 | 4 | 8 | |
| No | 48 | 26 | 22 | |
| Tumor location | 0.589 | |||
| Supratentorial | 39 | 21 | 18 | |
| Infratentorial | 21 | 9 | 12 | |
| Tumor size | 0.037* | |||
| <3cm | 27 | 9 | 18 | |
| ≥3cm | 33 | 21 | 12 | |
| WHO grade | 0.001** | |||
| I–II | 25 | 6 | 19 | |
| III–IV | 35 | 24 | 11 | |
Notes: *P < 0.05, **P < 0.01.
Univariate and Multivariate Analysis of Prognostic Factors for Overall Survival in Glioma Patients
| Variables | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Overall Survival | ||||||
| Gender | 0.814 | 0.450–1.472 | 0.496 | |||
| Age | 0.960 | 0.495–1.862 | 0.904 | |||
| Family history of cancer | 0.950 | 0.457–1.974 | 0.891 | |||
| Tumor location | 1.082 | 0.582–2.012 | 0.804 | |||
| Tumor size | 1.819 | 0.998–3.315 | 0.051 | |||
| WHO grade | 1.978 | 1.060–3.691 | 0.032* | 1.459 | 0.713–2.985 | 0.301 |
| circ_0079586 expression | 2.223 | 1.212–4.079 | 0.010* | 1.845 | 0.920–3.700 | 0.085 |
Notes: *P < 0.05. HR, hazard ratio; 95% CI, 95% confidence interval.
Figure 2Circ_0079586 promotes progression of GM cells. (A) qRT-PCR analysis of circ_0079586 expression in LN229 cells. (B) Circ_0079586 expression after transfection in U251 cells analyzed by qRT-PCR. (C) Analysis of CCK-8 assays depicting cell viability in LN229 and U251 cells after transfection. (D) Flow cytometric analysis depicting cell apoptosis in LN229 and U251 cells after transfection. (E) Wound healing assay data analysis was performed to detect cell migration in LN229 and U251 cells after transfection. Scale bar=50μm. (F) Transwell assay was used to detect cell invasion in LN229 and U251 cells after transfection. *p < 0.05, **p < 0.01.
Figure 3Circ_0079586 sponges miR-183-5p activity to elevate expression of MDM4. (A) qRT-PCR detection of the percentage of circ_0079586, GAPDH and U6 in the cytoplasm and nuclear fractions of LN229 and U251 cells. (B) Relative miRNA expression was detected in LN229 and U251 cells after transfection. (C) Schematic depicting the binding sites of miR-183-5p in circ_0079586/3ʹUTR of MDM4. (D) Correlation of expression of circ_0079586 and miR-183-5p in tissues from GM patients. (E) Luciferase reporter assay was conducted to evaluate the interaction between miR-183-5p and circ_0079586. (F) Relative MDM4 expression was detected in LN229 and U251 cells after transfection by qRT-PCR assay. (G) Western blot analysis for detecting MDM4 expression in LN229 and U251 cells after transfection. (H) Correlation analysis of expression of circ_0079586 and MDM4 in GM tissue samples. (I) Luciferase reporter assay was conducted to evaluate the interaction between 3ʹUTR of MDM4 and miR-183-5p. *p < 0.05, **p < 0.01.
Figure 4The oncogenic activity of circ_0079586 is dependent on the miR-183-5p/MDM4 signal axis. (A) Analysis of CCK-8 assay depicting cell viability after transfection in LN229 and U251 cells. (B) Analysis of the flow cytometric assay to evaluate cell apoptosis after transfection in LN229 and U251 cells. (C) Transwell assays were performed to evaluate cell invasion after transfection in LN229 and U251 cells. *p < 0.05, **p < 0.01.